About Pacific Diabetes Technologies
Pacific Diabetes Technologies is a Healthcare company based in Portland (United States) founded in 2011. It operates as an electronic diabetes management device for glucose sensing and hormone delivery. Pacific Diabetes Technologies has raised $6.52 million across 10 funding rounds from investors including NIH, HHS and Cascadia Venture Forum. Pacific Diabetes Technologies offers products and services including SynerG. Its focus areas include Life Sciences, Diabetes, Medical Devices and Therapeutic Devices. Its legal entity is Pacific Diabetes Technologies, Inc. Its competitors include Admetsys, TypeZero Technologies, Cellnovo, Ideal Medical Technologies and Animas and 3 more; 4 of its 8 listed competitors have raised funding.
Company details
Pacific Diabetes Technologies (PDT) aims to create an accessible integrated artificial pancreas which is a result of sensor chemistry with microelectronic fabrication technologies. The device is intended to be used for Type 1 diabetes or insulin-treated Type 2 diabetes and as of Nov 2015, it is not approved for human use. The first device of the company performs glucose sensing and hormone delivery, consisting of an insertion tool, electronic sensor module, insulin infusion line connector, and sensing catheter sensor house. This system provides diabetes management solution as it combines multiple amperometric glucose sensing units with insulin delivery in a single unified device.
- Headquarters Portland, United States
- SectorsHealthcare
- Email••••••••
- Website pacificdt.com
- Social LinkedIn Facebook
- Legal Name Pacific Diabetes Technologies, Inc
- Total Equity Funding$6.52M (USD)
in 10 rounds
- Latest Funding Round$2.92M (USD), Series A
Oct 2025
- InvestorsNIH
& 3 more
Products & Services of Pacific Diabetes Technologies
Pacific Diabetes Technologies offers a comprehensive portfolio of products and services, including SynerG.
A single device for continuous glucose monitoring and insulin site management.
Funding Insights of Pacific Diabetes Technologies
Pacific Diabetes Technologies has successfully raised a total of $6.52M across 10 strategic funding rounds. The most recent funding activity was a Series A round of $2.92 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $6.52M
- Total Rounds 10
- Last Round Series A — $2.92M
- First Round $292,000
(Sep 2012)
- Investors Count 4
All 10 funding rounds of Pacific Diabetes Technologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2025 | $2.92M | Series A | – | – | – |
| Mar 2025 | $2.06M | Series A | – | – | – |
| Sep 2023 | $1.54M | Series A | – | – | – |
| Sep 2019 | $1.8M | Grant | – | – | |
| Jun 2017 | – | Series A | – | – | |
| Aug 2016 | $224,150 | Grant | – | – | |
| Jun 2014 | $222,000 | Grant | – | – | |
| Sep 2013 | $222,735 | Grant | – | – | |
| Jan 2013 | $999,800 | Grant | – | – | |
| Sep 2012 | $292,000 | Grant | – | – |
4 investors in total: 4 institutional.
Investors in Pacific Diabetes Technologies
Pacific Diabetes Technologies has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and Cascadia Venture Forum.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | cascadiaventureforum.com | - | |
A charitable trust focused on healthcare and research funding. | – | helmsleytrust.org | New York, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States |
Investor details for Pacific Diabetes Technologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Pacific Diabetes Technologies
5 people are tracked at Pacific Diabetes Technologies (4 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Vladislav Milenkovic | Director Of Software Engineering | Leadership |
Peter Eckenberg | Chief Strategy Officer (cso) | Leadership |
Srikanth Iyengar | Chief Financial Officer | Leadership |
Thomas Seidl | CEO | Leadership |
Curt Jutzi | System Software Engineer | Team |
Complete people profiles for Pacific Diabetes Technologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Pacific Diabetes Technologies
3 dated milestones of Pacific Diabetes Technologies across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Pacific Diabetes Technologies is founded.
- Funding First funding round of $292K.
- Funding Latest funding round, Series A, of $2.9M.
Competitors of Pacific Diabetes Technologies
Pacific Diabetes Technologies has 8 listed competitors in our database, 4 of them funded. They include Admetsys, TypeZero Technologies, Cellnovo, Ideal Medical Technologies and Animas, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| admetsys.com | 2014 | Boston, United States | $50,000 | – | Provider of a closed-loop system for insulin and glucose delivery | |
| typezero.com | 2013 | Charlottesville, United States | $415,000 | – | Device for continuous glucose monitoring with manually operated insulin delivery | |
| cellnovo.com | 2002 | London, United Kingdom | $48.4M | – | Offers online slot gaming with bonuses, promotions, and secure interface. | |
| idealmedtech.com | 2013 | Asheville, United States | – | – | An AI-based artificial pancreas system is developed for ICU patients. | |
| animas.com | 1996 | West Chester, United States | – | – | Device for continuous glucose monitoring with manual insulin administration | |
| physiologicdevices.com | 2014 | Los Angeles, United States | – | – | Implantable insulin pump for diabetes treatment is being developed. | |
| glucotec.com | 2005 | Greenville, United States | $15.94M | – | Glycemic management system | |
| pancreum.com | 2011 | San Francisco, United States | – | – | Develops modular drug delivery systems and automated insulin delivery solutions. |
Detailed competitors of Pacific Diabetes Technologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Diabetes
10 companies that operate in the same segment as Pacific Diabetes Technologies (Diabetes), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of devices for continuous glucose monitoring and manual insulin delivery | 2008 | San Diego, California, United States | USD 100.73 M | USD 1.02 B | 2,650 | |
Wearable glucose monitoring patches are provided for real-time data tracking. | 1999 | San Diego, California, United States | USD 52.5 M | USD 4.66 B | 10,300 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Small molecule drugs for various therapeutic areas are developed. | 1995 | United States | USD 165 M | USD 49.8 M | 103 | |
Implantable continuous glucose monitoring systems are provided for diabetes management. | 1996 | Germantown, United States | USD 175.46 M | USD 22.47 M | 117 | |
Developer of a closed-loop automated insulin delivery system | 2014 | Milpitas, California, United States | USD 214.51 M | – | 133 | |
Provider of workforce healthcare solutions | 2015 | New York, New York, United States | USD 107.87 M | – | 166 | |
Diabetes care and reversal programs are provided to patients. | 2021 | Bengaluru, Karnataka, India | USD 26.7 M | USD 5.07 M | 677 | |
Provider of smart devices for diabetes management for patients and doctors | 2014 | San Francisco, California, United States | USD 237 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 253 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Pacific Diabetes Technologies
Pacific Diabetes Technologies was founded in 2011 and raised its 1st funding round 1 year after it was founded.
Pacific Diabetes Technologies is headquartered in Portland, United States. It is registered at Portland, Oregon, United States.
Pacific Diabetes Technologies is a funded company, having raised a total of $6.52M across 10 funding rounds to date. The company's 1st funding round was a Grant of $292K, raised on Sep 2012.
Pacific Diabetes Technologies (PDT) aims to create an accessible integrated artificial pancreas which is a result of sensor chemistry with microelectronic fabrication technologies. The device is intended to be used for Type 1 diabetes or insulin-treated Type 2 diabetes and as of Nov 2015, it is not approved for human use. The first device of the company performs glucose sensing and hormone delivery, consisting of an insertion tool, electronic sensor module, insulin infusion line connector, and sensing catheter sensor house. This system provides diabetes management solution as it combines multiple amperometric glucose sensing units with insulin delivery in a single unified device.
Pacific Diabetes Technologies's top competitors include Admetsys, TypeZero Technologies and Ideal Medical Technologies.
Pacific Diabetes Technologies offers SynerG.
Pacific Diabetes Technologies has 4 investors. Key investors include NIH, HHS, Cascadia Venture Forum, and Helmsley Charitable Trust.
Pacific Diabetes Technologies operates through Pacific Diabetes Technologies, Inc.